D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

onclive.com

Newly diagnosed multiple myeloma patients treated with D-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone) plus maintenance experienced prolonged PFS and higher MRD negativity rates compared to VRd. The PERSEUS trial showed D-VRd significantly reduced disease progression risk, particularly in revised standard-risk patients. D-VRd also extended PFS across R2-ISS stages, with notable benefits for stage II and III disease. MRD negativity rates at 10-5 and 10-6 were higher in the D-VRd group, especially in standard and high-risk cytogenetic subgroups.

cancernetwork.com

Combining subcutaneous daratumumab with bortezomib, lenalidomide, and dexamethasone (D-VRd) before autologous stem cell transplant (ASCT), followed by D-VRd consolidation and daratumumab plus lenalidomide (DR) maintenance, significantly improves minimal residual disease (MRD)–negative rates in transplant-eligible patients with newly diagnosed multiple myeloma, according to the PERSEUS trial. MRD-negative rates were higher in the D-VRd arm compared to the VRd arm at various time points and sensitivities, supporting D-VRd and DR maintenance as a new standard of care.

onclive.com

D-VRd followed by ASCT, D-VRd consolidation, and DR maintenance improved MRD negativity rates in transplant-eligible myeloma patients compared to VRd induction, ASCT, VRd consolidation, and lenalidomide maintenance, according to PERSEUS trial data. D-VRd showed higher MRD-negativity rates at 10^-5 and 10^-6 thresholds, sustained MRD negativity, and improved PFS, suggesting it as a new standard of care.